# Exploring the Unknown: Appreciating the Challenges of Non-compaction Cardiomyopathy

## TL;DR

This paper discusses the challenges of diagnosing and managing non-compaction cardiomyopathy, a rare heart condition marked by complex ventricular structures and inconsistent diagnostic and treatment protocols.

## Contribution

The paper highlights the need for standardized diagnostic and management guidelines to address under and over-diagnosis of non-compaction cardiomyopathy.

## Key findings

- NCCM is often under-diagnosed with echocardiography and over-diagnosed with advanced imaging like MRI.
- Treatment approaches are non-specific and include anticoagulation and guideline-directed medical therapy.
- Genetic research is emphasized as essential for developing tailored therapies and improving diagnostic accuracy.

## Abstract

Left ventricular non-compaction cardiomyopathy (LVNC), or non-compaction cardiomyopathy (NCCM), is defined by pronounced left ventricular trabeculations and deep intertrabecular recesses connecting with the ventricular cavity. Patients with NCCM can be asymptomatic or have severe complications, including heart failure, arrhythmias, thromboembolism, and sudden cardiac death. Our case discusses a patient with shortness of breath who was found to have a newly decreased ejection fraction. The workup revealed non-ischemic cardiomyopathy and cardiac MRI showed hyper-trabeculations consistent with NCCM. The patient was started on oral anticoagulation and guideline-directed medical therapy (GDMT) and discharged with an event monitor.
NCCM stands as a relatively rare and enigmatic condition, often veiled in ambiguity. The absence of standardized diagnostic and management protocols further complicates its clinical landscape. While echocardiography is the primary diagnostic tool, its tendency for under-diagnosis poses a significant challenge. Conversely, advanced imaging modalities like cardiac MRI may lead to instances of overdiagnosis. Treatment approaches are non-specific, incorporating GDMT, anticoagulation, implantable cardioverter-defibrillator placement, and genetic testing paired with counseling. Prioritizing genetic research is crucial to uncover tailored therapeutic interventions. Establishing consensus guidelines and refining diagnostic accuracy are pivotal steps toward mitigating the risks associated with under and over-diagnosis.